Acadia Pharmaceuticals ACAD Deferred Tax Assets and Other Non-Current Assets
Deferred Tax Assets and Other Non-Current Assets at other companies
Other financials
Where this comes from
Reported directly by Acadia Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:OtherAssetsNoncurrent.
The official record: Acadia Pharmaceuticals’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Acadia Pharmaceuticals's deferred tax assets and other non-current assets.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Acadia Pharmaceuticals's deferred tax assets and other non-current assets?
- Acadia Pharmaceuticals (ACAD) reported deferred tax assets and other non-current assets of $3.93M in Q1 2026.
- How has Acadia Pharmaceuticals's deferred tax assets and other non-current assets changed year-over-year?
- Acadia Pharmaceuticals's deferred tax assets and other non-current assets increased by 170.0% year-over-year, from $1.46M to $3.93M.
- What is the long-term trend for Acadia Pharmaceuticals's deferred tax assets and other non-current assets?
- Over 5 years (2020 to 2025), Acadia Pharmaceuticals's deferred tax assets and other non-current assets has grown at a 18.3% compound annual growth rate (CAGR), from $1.68M to $3.9M.